5-O-phosphono-alpha-D-ribofuranosyl diphosphate

Identification

Name
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
Accession Number
DB01632  (EXPT02663)
Type
Small Molecule
Groups
Approved, Experimental, Investigational
Description

The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides.

Structure
Thumb
Synonyms
  • 5-O-phosphono-α-D-ribofuranosyl diphosphate
  • 5-Phospho-alpha-D-ribose 1-diphosphate
  • 5-Phosphoribosyl 1-pyrophosphate
  • 5-Phosphoribosyl diphosphate
  • Phosphoribosyl pyrophosphate
  • Phosphoribosylpyrophosphate
  • PRib-PP
  • PRPP
  • α-D-ribofuranose 5-(dihydrogen phosphate) 1-(trihydrogen diphosphate)
Categories
UNII
Not Available
CAS number
13270-65-0
Weight
Average: 390.0696
Monoisotopic: 389.95181466
Chemical Formula
C5H13O14P3
InChI Key
PQGCEDQWHSBAJP-TXICZTDVSA-N
InChI
InChI=1S/C5H13O14P3/c6-3-2(1-16-20(8,9)10)17-5(4(3)7)18-22(14,15)19-21(11,12)13/h2-7H,1H2,(H,14,15)(H2,8,9,10)(H2,11,12,13)/t2-,3-,4-,5-/m1/s1
IUPAC Name
[({[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]oxy}(hydroxy)phosphoryl)oxy]phosphonic acid
SMILES
O[C@H]1[C@@H](O)[C@@H](OP(O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UHypoxanthine-guanine phosphoribosyltransferaseNot AvailableTrypanosoma cruzi
UAdenine phosphoribosyltransferaseNot AvailableHuman
UAnthranilate phosphoribosyltransferaseNot AvailableErwinia carotovora
UHypoxanthine-guanine phosphoribosyltransferaseNot AvailableHuman
UOrotate phosphoribosyltransferaseNot AvailableSalmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)
UUridine-cytidine kinase-like 1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
AICA-RibosiduriaDisease
Xanthine Dehydrogenase Deficiency (Xanthinuria)Disease
Azathioprine Action PathwayDrug action
Succinic Semialdehyde Dehydrogenase DeficiencyDisease
Histidine BiosynthesisMetabolic
NAD BiosynthesisMetabolic
Thiamin Diphosphate BiosynthesisMetabolic
NAD MetabolismMetabolic
Pentose Phosphate PathwayMetabolic
Pyrimidine MetabolismMetabolic
Nicotinate and Nicotinamide MetabolismMetabolic
Purine MetabolismMetabolic
2-Hydroxyglutric Aciduria (D and L Form)Disease
Dihydropyrimidinase DeficiencyDisease
Purine Nucleoside Phosphorylase DeficiencyDisease
Mercaptopurine Action PathwayDrug action
Transaldolase DeficiencyDisease
Adenine Phosphoribosyltransferase Deficiency (APRT)Disease
Adenine and Adenosine Salvage IIIMetabolic
Tryptophan MetabolismMetabolic
Purine Nucleotides De Novo Biosynthesis Metabolic
beta-Ureidopropionase DeficiencyDisease
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)Disease
Hyperinsulinism-Hyperammonemia SyndromeDisease
Thioguanine Action PathwayDrug action
Mercaptopurine Metabolism PathwayDrug metabolism
Thioguanine Metabolism PathwayDrug metabolism
Guanine and Guanosine SalvageMetabolic
Histidine BiosynthesisMetabolic
Histidine MetabolismMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0000280
KEGG Compound
C00119
PubChem Compound
7339
PubChem Substance
46506467
ChemSpider
7062
BindingDB
25315
ChEBI
17111
HET
PRP
PDB Entries
1d6n / 1fsg / 1i0i / 1i0l / 1i13 / 1i14 / 1jls / 1kgz / 1l1r / 1lh0
show 62 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentKnee Osteoarthritis (Knee OA)1
0Enrolling by InvitationTreatmentKnee Pain Chronic / Pes Anserinus Bursitis / Status-Post Total Knee Arthroplasty1
0Not Yet RecruitingTreatmentInfertilities1
1CompletedSupportive CareChronic Ulcer1
1CompletedTreatmentBone Resorption1
1CompletedTreatmentOsteoarthritis (OA)1
1CompletedTreatmentRotator Cuff Syndrome / Rotator Cuff Tendinitis / Shoulder Pain / Spinal Cord Injuries (SCI)1
1CompletedTreatmentTraumatic Bone Cyst1
1Not Yet RecruitingTreatmentInterstitial Cystitis1
1TerminatedTreatmentRotator Cuff Syndrome1
1, 2CompletedTreatmentChronic Ulcer1
1, 2CompletedTreatmentPrevious Incision / Scar; Previous Cesarean Section1
1, 2RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1, 2Unknown StatusTreatmentKnee Osteoarthritis (Knee OA)1
2Active Not RecruitingTreatmentLateral Epicondylitis1
2Active Not RecruitingTreatmentPatellar Tendinopathy1
2CompletedPreventionHaemophilus Infections / Haemophilus Influenzae Type B / Meningococcal Infections / Neisseria Meningitidis1
2CompletedSupportive CareWound Healing, Adipose Tissue Extract, Plateelt Rich Plasma, Skin Graft Donor Site1
2CompletedTreatmentAcute Hamstring Muscle Strain Injury1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)1
2Not Yet RecruitingSupportive CareUnilateral Cleft Lip1
2Not Yet RecruitingTreatmentAchilles Tendinitis / Lateral Epicondylitis / Rotator Cuff Syndrome1
2Not Yet RecruitingTreatmentCesarean Section Complications1
2Not Yet RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
2RecruitingTreatmentAsherman's Syndrome / Infertilities1
2RecruitingTreatmentEndometrial Disorder / Endometrial Thickness Not Growing Under Estrogen Stimulation / Thin Endometrium1
2RecruitingTreatmentKnee Osteoarthritis (Knee OA)3
2RecruitingTreatmentMuscle Injuries1
2RecruitingTreatmentOsteoarthritis (OA)2
2RecruitingTreatmentPatellar Tendinitis1
2, 3Not Yet RecruitingPreventionGestational Diabetes Mellitus (GDM) / Wound Complications1
2, 3RecruitingPreventionPelvic Floor Disorders1
3Active Not RecruitingTreatmentUlcers1
3CompletedPreventionEndoscopic Mucosal Resection / Endoscopic Submucosal Dissection / Platelet-rich Plasma1
3CompletedTreatmentArthroplasty, Replacement1
3CompletedTreatmentEndoscopic Submucosal Dissection / Platelet-rich Plasma1
3CompletedTreatmentKnee Osteoarthritis (Knee OA)1
3CompletedTreatmentMuscle Injuries1
3CompletedTreatmentOsteoarthritis (OA)1
3RecruitingTreatmentOsteoarthritis, Hip1
3Unknown StatusTreatmentEye Dryness / Sjögren's Syndrome1
4Active Not RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
4Active Not RecruitingTreatmentPost Operative Pain1
4CompletedTreatmentKnee Chondropathy / Knee Osteoarthritis (Knee OA)1
4CompletedTreatmentNeoplasms, Breast1
4Enrolling by InvitationTreatmentBack Pain Lower Back Chronic / Bupivacaine / Injection Site / Lidocaine / Platelet / Platelet Rich Plasma / Sacroiliac; Backache / Sacroiliitis / Treatments / Ultrasound Therapy; Complications1
4RecruitingTreatmentFemoroacetabular Impingement1
4RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
4RecruitingTreatmentOsteoarthritis (OA)1
4RecruitingTreatmentOsteoarthritis (OA) / Shoulder Pain1
4TerminatedTreatmentHip Pain / Tendinopathy1
4WithdrawnTreatmentRectal Fistulas1
Not AvailableCompletedPreventionBlood Loss / Pain NOS1
Not AvailableCompletedPreventionElective Foot and Ankle Surgery1
Not AvailableCompletedTreatmentAtrophic Scar1
Not AvailableCompletedTreatmentDiabetic Peripheral Neuropathy (DPN)1
Not AvailableCompletedTreatmentKnee Chondropathy / Knee Early Osteoarthritis1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentLateral Epicondylitis1
Not AvailableCompletedTreatmentPain NOS1
Not AvailableCompletedTreatmentPeriorbital Hyperpigmentation1
Not AvailableCompletedTreatmentPlatelet-rich Plasma / Wound Healing Delayed1
Not AvailableCompletedTreatmentTendinopathy1
Not AvailableEnrolling by InvitationTreatmentChondral Lesions / Femoroacetabular Impingement1
Not AvailableEnrolling by InvitationTreatmentOsteoarthritis, Hip1
Not AvailableNot Yet RecruitingTreatmentCarious Teeth1
Not AvailableNot Yet RecruitingTreatmentOsteoarthritis Thumb1
Not AvailableNot Yet RecruitingTreatmentVitiligo1
Not AvailableRecruitingTreatmentBack Pain Lower Back1
Not AvailableRecruitingTreatmentFracture Bone1
Not AvailableRecruitingTreatmentOsteoarthritis, Hip1
Not AvailableRecruitingTreatmentOsteochondritis Dissecans1
Not AvailableRecruitingTreatmentPlantar fascial fibromatosis1
Not AvailableTerminatedTreatmentShoulder Impingement Syndrome1
Not AvailableUnknown StatusTreatmentAndrogenetic Alopecia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.6 mg/mLALOGPS
logP-0.74ALOGPS
logP-3ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)1.09ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge-4ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area229.74 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity62.58 m3·mol-1ChemAxon
Polarizability27.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9864
Blood Brain Barrier+0.924
Caco-2 permeable-0.7323
P-glycoprotein substrateNon-substrate0.7206
P-glycoprotein inhibitor INon-inhibitor0.8258
P-glycoprotein inhibitor IINon-inhibitor0.9919
Renal organic cation transporterNon-inhibitor0.9101
CYP450 2C9 substrateNon-substrate0.8024
CYP450 2D6 substrateNon-substrate0.8346
CYP450 3A4 substrateNon-substrate0.5843
CYP450 1A2 substrateNon-inhibitor0.8892
CYP450 2C9 inhibitorNon-inhibitor0.886
CYP450 2D6 inhibitorNon-inhibitor0.9188
CYP450 2C19 inhibitorNon-inhibitor0.8792
CYP450 3A4 inhibitorNon-inhibitor0.9727
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9715
Ames testNon AMES toxic0.7781
CarcinogenicityNon-carcinogens0.9024
BiodegradationReady biodegradable0.7128
Rat acute toxicity2.0708 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.923
hERG inhibition (predictor II)Non-inhibitor0.8905
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-01tc-2934000000-e0fcfd13254fd3781439
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dm-6593000000-b295e74d43b0dc625e47
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01r2-7920000000-a021603f22f19c083511
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0509000000-54231bd8f000ab2dd4a0
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9301000000-447b996f7510c6ae354b
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9000000000-54f70df2270a3e4f67d2

Taxonomy

Description
This compound belongs to the class of organic compounds known as pentose phosphates. These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Pentose phosphates
Alternative Parents
Organic pyrophosphates / Monosaccharide phosphates / Monoalkyl phosphates / Tetrahydrofurans / Secondary alcohols / 1,2-diols / Oxacyclic compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Pentose phosphate / Pentose-5-phosphate / Monosaccharide phosphate / Organic pyrophosphate / Monoalkyl phosphate / Organic phosphoric acid derivative / Phosphoric acid ester / Alkyl phosphate / Tetrahydrofuran / 1,2-diol
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
5-O-phosphono-D-ribofuranosyl diphosphate (CHEBI:17111)

Targets

Kind
Protein
Organism
Trypanosoma cruzi
Pharmacological action
Unknown
General Function
Hypoxanthine phosphoribosyltransferase activity
Specific Function
Not Available
Gene Name
HGPRTase
Uniprot ID
Q27796
Uniprot Name
Hypoxanthine-guanine phosphoribosyltransferase
Molecular Weight
25529.02 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Amp binding
Specific Function
Catalyzes a salvage reaction resulting in the formation of AMP, that is energically less costly than de novo synthesis.
Gene Name
APRT
Uniprot ID
P07741
Uniprot Name
Adenine phosphoribosyltransferase
Molecular Weight
19607.535 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Erwinia carotovora
Pharmacological action
Unknown
General Function
Magnesium ion binding
Specific Function
Catalyzes the transfer of the phosphoribosyl group of 5-phosphorylribose-1-pyrophosphate (PRPP) to anthranilate to yield N-(5'-phosphoribosyl)-anthranilate (PRA).
Gene Name
trpD
Uniprot ID
Q8VP84
Uniprot Name
Anthranilate phosphoribosyltransferase
Molecular Weight
37017.84 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5-phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Plays a central role...
Gene Name
HPRT1
Uniprot ID
P00492
Uniprot Name
Hypoxanthine-guanine phosphoribosyltransferase
Molecular Weight
24579.155 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)
Pharmacological action
Unknown
General Function
Orotate phosphoribosyltransferase activity
Specific Function
Catalyzes the transfer of a ribosyl phosphate group from 5-phosphoribose 1-diphosphate to orotate, leading to the formation of orotidine monophosphate (OMP).
Gene Name
pyrE
Uniprot ID
P08870
Uniprot Name
Orotate phosphoribosyltransferase
Molecular Weight
23561.74 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Uridine kinase activity
Specific Function
May contribute to UTP accumulation needed for blast transformation and proliferation.
Gene Name
UCKL1
Uniprot ID
Q9NWZ5
Uniprot Name
Uridine-cytidine kinase-like 1
Molecular Weight
61140.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on November 02, 2018 05:04